#	Pagina
attuale pagina	/open-fp7/projects/97364/index.html

FLU-PHARM

New drugs targeting influenza virus polymerase

Coordinatore	EUROPEAN MOLECULAR BIOLOGY LABORATORY Organization address address: Meyerhofstrasse 1 city: HEIDELBERG postcode: 69117 contact info Titolo: Mrs. Nome: Sonja Cognome: Noss Email: send email Telefono: 4962210000000 Fax: 4962210000000
Nazionalità Coordinatore	Germany [DE]
Totale costo	8˙318˙210 €
EC contributo	5˙998˙757 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-INFLUENZA-2010
Funding Scheme	CP-FP
Anno di inizio	2010
Periodo (anno-mese-giorno)	2010-11-01 - 2015-04-30

Partecipanti

#	participant	country	role	EC contrib. [€]
1	EUROPEAN MOLECULAR BIOLOGY LABORATORY Organization address address: Meyerhofstrasse 1 city: HEIDELBERG postcode: 69117 contact info Titolo: Mrs. Nome: Sonja Cognome: Noss Email: send email Telefono: 4962210000000 Fax: 4962210000000	DE (HEIDELBERG)	coordinator	991˙222.00
2	SAVIRA PHARMACEUTICALS GMBH Organization address address: VETERINARPLATZ 1 city: WIEN postcode: 1210 contact info Titolo: Dr. Nome: Dirk Cognome: Classen-Houben Email: send email Telefono: +43 1 250 77 59 04 Fax: +43 1 250 77 59 99	AT (WIEN)	participant	1˙790˙507.00
3	ADVANCED TECHNOLOGY CORPORATION SA Organization address address: Inst. Pathology B23 CHU Sart Tilman city: LIEGE postcode: 4000 contact info Titolo: Dr. Nome: Patrice Cognome: Chiap Email: send email Telefono: +32 4 3664350 Fax: +32 4 3662481	BE (LIEGE)	participant	715˙075.00
4	"PRESTWICK CHEMICAL, INC." Organization address address: "K STREET, NW, SUITE 520 1825" city: WASHINGTON postcode: 20006 contact info Titolo: Prof. Nome: Thierry Cognome: Langer Email: send email Telefono: +33 369 20 16 00 Fax: +33 369 20 16 17	US (WASHINGTON)	participant	653˙190.00
5	AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS Organization address address: CALLE SERRANO 117 city: MADRID postcode: 28006 contact info Titolo: Mr. Nome: Carlos Manuel Cognome: Abad Ruiz Email: send email Telefono: +34 91 5668852 Fax: +34 91 5668913	ES (MADRID)	participant	367˙785.00
6	INSTITUT PASTEUR Organization address address: RUE DU DOCTEUR ROUX 25-28 city: PARIS CEDEX 15 postcode: 75724 contact info Titolo: Dr. Nome: Thierry Cognome: Planchenault Email: send email Telefono: +33 1 44389113 Fax: +33 1 40613940	FR (PARIS CEDEX 15)	participant	350˙000.00
7	UNIVERSITE JOSEPH FOURIER GRENOBLE 1 Organization address address: "Avenue Centrale, Domaine Universitaire 621" city: GRENOBLE postcode: 38041 contact info Titolo: Ms. Nome: Leslie Cognome: Hollett Email: send email Telefono: +33 4 76514488 Fax: +33 4 76635956	FR (GRENOBLE)	participant	303˙528.00
8	VIROLOGICKY USTAV SLOVENSKEJ AKADEMIE VIED Organization address address: Dubravska Cesta 9 city: BRATISLAVA postcode: 84505 contact info Titolo: Ms. Nome: Irena Cognome: Ginzeryová Email: send email Telefono: +421 2 59302403 Fax: +421 2 54774284	SK (BRATISLAVA)	participant	279˙750.00
9	HEINRICH-PETTE-INSTITUT FUER EXPERIMENTELLE VIROLOGIE UND IMMUNOLOGIE AN DER UNIVERSITAET HAMBURG Organization address address: Martinistrasse 52 city: HAMBURG postcode: 20251 contact info Titolo: Dr. Nome: Nicole Cognome: Nolting Email: send email Telefono: +49 40 48051104 Fax: +49 40 48051103	DE (HAMBURG)	participant	199˙800.00
10	INTE:LIGAND SOFTWARE-ENTWICKLUNGS- UND CONSULTING GMBH Organization address address: Clemens-Maria Hofbauer Gasse 6 city: MARIA ENZERSDORF postcode: 2344 contact info Titolo: Dr. Nome: Gerhard Cognome: Wolber Email: send email Telefono: +43 699 1507 5000 Fax: +43 1 8174955 1371	AT (MARIA ENZERSDORF)	participant	178˙100.00
11	PHILIPPS UNIVERSITAET MARBURG Organization address address: Biegenstrasse 10 city: MARBURG postcode: 35032 contact info Titolo: Dr. Nome: Christian Cognome: Veldman Email: send email Telefono: +49 6421 2826022 Fax: +49 6421 2826382	DE (MARBURG)	participant	163˙800.00
12	MEDIZINISCHE UNIVERSITAET WIEN Organization address address: SPITALGASSE 23 city: WIEN postcode: 1090 contact info Titolo: Prof. Nome: Markus Cognome: Müller Email: send email Telefono: 431404000000 Fax: 431404000000	AT (WIEN)	participant	6˙000.00

Mappa

Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

strains influenza replication cellular drugs academic expertise avian pandemic recent structure world n preclinical drug public function pathogenic inhibitors anti resistance h polymerase viral

Obiettivo del progetto (Objective)

'The 2009 H1N1 pandemic and the ongoing threat of highly pathogenic H5N1 strains have focused attention worldwide on the urgent need for effective anti-influenza drug options when the public is not protected by vaccination. The need is pressing since several circulating strains are resistant to currently stock-piled anti-neuraminidase drugs. In this project, we will exploit our recent advances in the detailed mechanistic understanding of the structure and function of the viral polymerase, the replication machine of the virus, to develop new drug candidates that inhibit viral replication in infected cells. The polymerase is an excellent drug target as it is highly conserved in all influenza A strains, whether of avian, swine or human origin. The project consortium includes 12 academic and SME partners from 6 European countries chosen for their expertise and complementarity. The focused drug design programme will start with already existing patented small molecule hits against two different polymerase active site targets and use structure-based medicinal chemistry expertise to arrive at optimized leads to enter preclinical studies. The aim is to take one preclinical candidate to phase 1 clinical trials, with contingency plans in place to cover setbacks. In parallel, a world-leading network of European academic labs will continue fundamental research on influenza polymerase atomic structure, cellular function and role in inter-species transmission, which will feed back into the drug design programme with enhanced assays for polymerase inhibitors, improved understanding of how the inhibitors work in the cellular context and potential resistance mechanisms, as well as providing new targets for future anti-influenza drug-design. If successful, the project will provide new opportunities to treat both seasonal and pandemic flu and thus can have an enormous impact on world-wide public health and well-being as well as the competitiveness of the European pharmaceutical sector'

Introduzione (Teaser)

The 2009 pandemic and recent outbreaks of highly pathogenic avian influenza strains have highlighted the need for effective anti-viral drugs. A broad choice of drugs is necessary for treatment before a new vaccine becomes available to counter the problem of viral resistance.